Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spartalizumab + trametinib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of spartalizumab and trametinib consists of **spartalizumab**, a monoclonal antibody that targets and inhibits the **programmed death receptor 1 (PD-1)**, and **trametinib**, a small molecule inhibitor of **mitogen-activated protein kinase kinase 1 (MEK1)** and **mitogen-activated protein kinase kinase 2 (MEK2)**. This combination is being investigated primarily for the treatment of **BRAF V600-mutant unresectable or metastatic melanoma**. Spartalizumab enhances antitumor immunity by blocking PD-1 and restoring T-cell activity, while trametinib blocks MEK1/2 in the MAPK pathway, inhibiting cell proliferation and survival. The COMBI-i trial evaluates this regimen, typically in combination with dabrafenib[3][5][7].
- Other names
- spartalizumab + trametinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on spartalizumab + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spartalizumab + trametinib.